Syros Pharma begins first in-human trial of oral CDK7 inhibitor
Category: #health  By Mateen Dalal  Date: 2020-01-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Syros Pharma begins first in-human trial of oral CDK7 inhibitor

Syros Pharmaceuticals, a leading biotechnology company focused upon developing medicines for controlling and altering expression of genes, recently announced that the first patient has been dosed in the clinical trial of SY-5609, with a potent (CDK7) oral cyclin-dependent kinase 7 inhibitor.

The Phase 1 clinical trial is currently enrolling patients with advanced colorectal, breast, ovarian, and lung cancer, with solid tumors of any histology that possess Rb pathway alterations.

Kyriakos P. Papadopoulos, a clinical investigator in the trial and Co-Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) was reportedly quoted saying that SY-5609 seems to be a promising new approach for treating a number of cancers, that have turned out unsuccessful with other targeted approaches. The team is looking forward to gain opportunities to accelerate the development of new treatments to improve lives of patients and come up with a strong antidote against cancer.

Papadopoulos added saying that SY-5609 has shown compelling preclinical activity in a range of cancer models, and the team is thrilled to further investigate it in this Phase 1 study.

As per sources close to the matter, SY-5609 has demonstrated significant anti-tumor activity, including complete regressions in several preclinical models of solid tumors, including colorectal, ovarian, lung and breast cancers, at doses below the MTD (maximum tolerated dose).

In preclinical studies of lung, ovarian, and breast cancers, more sustained responses were linked with the presence of Rb pathway alterations. The trial has also demonstrated anti-tumor activity in combination with fulvestrant in treatment-resistant models of estrogen receptor-positive breast cancer, along with those resistant to both cyclin-dependent kinase 4/6 inhibitor and fulvestrant.

The main objective of the dose escalation in the trial is to assess the tolerability and safety of escalating doses of SY-5609, aimed at establishing a maximum tolerated dose. Other objectives include assessments of pharmacokinetics, pharmacodynamics, anti-tumor activity, potential predictive biomarkers, including Rb pathway alterations. Multiple cohorts are planned to further evaluate the anti-tumor activity of SY-5609 as a single agent, as well as in combination with other therapies, in a future expansion of the Phase 1 trial.
 

Source Credit: https://ir.syros.com/press-releases/detail/182/syros-announces-first-patient-dosed-in-phase-1-clinical

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...